| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $36.6M | +13.8% |
| SG&A Expense | $5.9M | -1.3% |
| Operating Income | -$42.4M | -11.5% |
| Net Income | -$47.0M | -14.6% |
| EPS (Basic) | -$0.76 | -2.7% |
| EPS (Diluted) | -$0.76 | -2.7% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $15.1M | -41.1% |
| Current Assets | $17.3M | -37.7% |
| Total Assets | $17.5M | -38.0% |
| Current Liabilities | $35.4M | +125.9% |
| Total Liabilities | $120.6M | +36.3% |
| Stockholders' Equity | -$104.8M | -69.1% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$41.8M | -26.7% |
| Investing Cash Flow | $0 | — |
| Financing Cash Flow | $31.2M | -22.0% |